SL 701

Drug Profile

SL 701

Alternative Names: Brain cancer vaccine - Stemline Therapeutics; SL-701

Latest Information Update: 20 Mar 2017

Price : $50

At a glance

  • Originator University of Pittsburgh
  • Developer Stemline Therapeutics; University of Pittsburgh
  • Class Brain cancer vaccines; Dendritic cell vaccines; Peptides; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Glioblastoma
  • Phase I/II Glioma

Most Recent Events

  • 16 Mar 2017 Stemline Therapeutics completes enrolment in a phase I/II trial for Glioblastoma (In adults, Recurrent, Second-line therapy or greater) in USA
  • 22 Nov 2016 Efficacy and adverse events data from a phase I/II trial in Glioblastoma released by Stemline Therapeutics
  • 19 May 2016 Phase-II clinical trials in Glioblastoma (Recurrent, Second-line therapy or greater, In adults, Combination) in USA (SC) (NCT02078648)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top